PBAC Public Summary Documents – July 2025
Page last updated: 31 October 2025
Public Summary Documents relating to the July 2025 PBAC meeting.
- Abaloparatide; Solution for injection 3 mg in 1.5 mL pre-filled pen; Eladynos®
- Abiraterone Acetate and Prednisolone; Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg; Andriga-10
- Acalabrutinib; Tablet 100 mg; Calquence®
- Aflibercept; Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre filled syringe, Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL); Afqlir®, Enzeevu™
- Apomorphine; Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL; Movapo® POD
- Aripiprazole; Powder for injection 300 mg (as monohydrate) with diluent in single dose pre-filled syringe , Powder for injection 400 mg (as monohydrate) with diluent in single dose pre-filled syringe; Abilify Maintena®
- Brentuximab Vedotin; Powder for I.V. infusion 50 mg; Adcetris®
- Brexpiprazole; Tablet 500 micrograms; Rexulti®
- Cabozantinib; Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
- Calcipotriol with betamethasone dipropionate; Cream containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g; Wynzora®
- Cannabidiol; Oral liquid 100 mg per mL, 100 mL; Epidyolex®
- Enoxaparin; Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe, Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe, Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe, Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe, Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe, Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe; Enoxaject®
- Etanercept; Injections 50 mg in 1 mL single use pre-filled syringes, 4; Nepexto®
- Futibatinib; Tablet 4 mg; Lytgobi®
- Glofitamab; Solution concentrate for I.V. infusion 2.5 mg in 2.5 mL, Solution concentrate for I.V. infusion 10 mg in 10 mL; Columvi®
- Guselkumab; Solution for I.V. infusion 200 mg in 20 mL vial, Injection 100 mg in 1 mL single use pre-filled pen, Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg in 1 mL single use pre-filled syringe, Injection 200 mg in 2 mL single use pre-filled syringe; Tremfya®
- IncobotulinumtoxinA; Lyophilised powder for injection 100 units; Xeomin®
- Infliximab; Powder for I.V. infusion 100 mg; Remsima®
- Insulin degludec; Solution for injection 100 units per mL; Tresiba® Penfill®
- Leniolisib; Tablet 70 mg; Joenja®
- Methadone; Tablet 5 mg; Methadone-AFT
- Ocrelizumab; Solution for subcutaneous injection 920 mg in 23 mL ; Ocrevus®
- Osimertinib; Tablet 40 mg, Tablet 80 mg; Tagrisso®
- Paliperidone; I.M. injection (modified release) 25 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 50 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 75 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 100 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 150 mg (as palmitate) in pre-filled syringe; Paljuna Monthly
- Palopegteriparatide; Solution for subcutaneous injection 168 micrograms in 0.56 mL pre-filled pen, Solution for subcutaneous injection 294 micrograms in 0.98 mL pre-filled pen, Solution for subcutaneous injection 420 micrograms in 1.4 mL pre-filled pen; Yorvipath®
- Pegunigalsidase Alfa; Solution for I.V. injection 20 mg in 10 mL vial; Elfabrio®
- Tacrolimus; Ointment 1 mg per g, 30 g; aZematop®
- Teriparatide; Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen; Ritosa
The following Public Summary Documents have been updated:
November 2024 PBAC meeting
March 2025 PBAC meeting
